An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers

Size: px
Start display at page:

Download "An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers"

Transcription

1 An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers Theresa Steckel, RN, BSN Newborn Screening Quality Assurance and Education Coordinator Oklahoma State Department of Health

2 Two-Tier Screen Immunoreactive Trypsinogen (IRT) Values Out-of-range: 65 ng/ml (Performed by OSDH on each Filter Paper) Yes Out-of-Range No DNA Analysis Performed by OSDH Public Health Lab Report In-Range

3 Mutation Panel = F508 A455E kbC>T 2183AA>G I G>A W1282X 2307insA G542X R560T N1303K Y1092X G85E R553X 394delTT M1101K G551D Y122X S1255X G>A R347H 3876delA 621+1G>T 2184delA V520F 3905insT 711+1G>T G>A A559T G>A S549N R334W R1162X S549R T>G 1078delT R347P 3659delC G>T R117H I148T Reflex: F508C,I507V,I506V, 5T/7T/9T

4 IRT ng/ml Yes CF Mutation(s) Detected No Refer for Sweat Test & Targeted CF Newborn Screening Genetic Counseling Not Consistent with Cystic Fibrosis

5 Yes IRT > 170 ng/ml CF Mutation(s) Detected No Refer for Sweat Test & Targeted CF Newborn Screening Genetic Counseling As of January 1, 2007 OSDH does not follow zero mutations. IRT> 65 with Zero Mutations "Not Consistent with Cystic Fibrosis unless symptomatic or if there is a Family History of CF. Protocol to

6 Sweat Testing OSDH contracts with two sweat testing centers in Oklahoma Each Center provides sweat testing for OSDH referrals on a designated newborn screening day Tulsa: Friday Oklahoma City: Monday

7 Confirmatory Sweat Testing Two Sweat Testing Centers Oklahoma City Tulsa

8 Sweat Testing Funded by newborn screening fee $75.00 per sweat test Do not pay for QNS The Sweat Testing Center forwards a copy of the sweat test result to short-term-followup (STFU) STFU forwards the sweat test result to the PCP by fax

9 Genetic Counseling OSDH contracts with The University of Oklahoma, Health Sciences Center/ Depart of Pediatrics, Section of Genetics Genetic Counselors are housed in Oklahoma City and travel to Tulsa weekly

10 Genetic Counseling Occurs at the time of sweat testing Contract requires face-to-face counseling by Board Certified or Board Eligible Genetic Counselor GC meets with the family to interpret sweat test results and communicate complex genetic information including the results of the DNA mutation analysis

11 Genetic Counseling Funded by the Newborn Screening Fee Cost for Genetic Counseling Session Oklahoma City: $ Tulsa: $ (professional time) Other Costs Travel to Tulsa

12 Coordinating & Scheduling Sweat Test & Genetic Counseling STFU notifies PCP Family Appropriate sweat testing center Genetic Counselor

13 PCP is notified of out-of range CF result Fax, Phone Call, and Letter The PCP is responsible for Notifying the family and Scheduling the sweat test Provided with Mother s contact information, CF Fact Sheet, and Instructions to schedule the sweat test.

14 Parents receive a letter from STFU Screened for Cystic Fibrosis Your baby s test indicates more testing is needed. Test is called a sweat test. Instructed to contact their health care provider. Provided with contact information for the sweat testing centers. Directions to the sweat testing center with a map. Free genetic counseling provided.

15 Coordinating Sweat Testing and Genetic Counseling Sweat Testing Center (Tulsa or OKC) Probable testing center notified of Newborn Screening referral via fax from STFU. Genetic Counselor Notified of Newborn Screening result and referral via fax from STFU. Probable testing center is indicated on the fax transmittal The testing centers communicate directly with the genetic counselors to coordinate the counseling appointments.

16 Genetic Counseling Follow-Up Genetic Counselor submits a Report Form to STFU following the genetic counseling session Provides documentation of components covered during the genetic counseling session. Sweat Test Results Genetic Information Recommendations

17 GC Report Form Developed by OSDH Genetic Counselor during the planning stages. Ensures quality of the services provided. Ensures specific information is communicated to the family. Facilitates consistency of services provided. Check Box format

18 Report Form General Information Infant s Name Date of Counseling Session Name of Genetic Counselor Family Members Present Date of Sweat Test and Time Sweat testing site Sweat test results DNA results (one or two mutations) Family Carrier Testing (Yes, No, Undecided) not provided by OSDH

19 Report Form Check all that apply: No show for sweat testing No show for genetic counseling Family refused counseling Session not performed on the same day as the sweat test

20 Report Form Client Assessment Information Provided and Discussed Counseling Components (Varies by Test Results) No Mutations, negative sweat One mutation, negative sweat Two mutations, negative sweat Zero to One mutation, positive sweat Two mutations, positive sweat test Zero to two mutations, with borderline sweat

21 Zero to two mutations present, with borderline sweat test Two (status mutations unknown) present, the session negative shall sweat include: test the session shall include: Natural history including variability of clinical phenotype Natural Limitations History of test including variability of clinical phenotype No Mutations, of Negative Sweat including Test Explanation of inheritance pattern to include recurrence risk risk if Explanation applicable Limitations of risk of testing to other family members and plan for relaying information Explanation Other causes of risk of to elevated other family IRT members (possible and carrier plan for of Future relaying mutation reproductive information not on options panel) Further Future Encouraged testing reproductive options regular options (repeat check-ups DNA analysis with pediatrician and parental carrier testing) Further testing options Discussed genotype-phenotype correlations if if known Recommended additional repeat genetic counseling if indicated Addressed Referred to psychosocial CF specialty issues clinic if including two mutations anticipatory were guidance present and Addressed reaction psychosocial to diagnosis issues including anticipatory Referred guidance to and CF reaction specialty to clinic diagnosis and provided resources Provided resources

22 GC Letter to family Summarizes session Lists IRT DNA Mutations Confirmatory Sweat Test Results Follow-Up Recommendations Maximum 14 days following session Forwarded to PCP by STFU

23 Referral to CF Center Infants are not referred to the CF Center until after sweat testing. Positive Sweat Test Two Mutations Two Borderlines Sweat Test

24 Lessons Learned Learning Curve for providers Second Tier Out-of-range results: Not Consistent with CF Sweat Test Referrals Contracting with Genetic Counselors Style of communication and follow-up different then OSDH. Worked closely with them to refined follow-up letter. Timing of letter (14 days) Insist counseling is face-to-face Meticulous planning eventually resulted in a successful and streamlined screening protocol.

25 Challenges LBW infants - Extended care in NICU Sweat test performed in non-contracted lab Consulted with specialist. Genetic Counseling Scheduled at another time. A few infants were scheduled on the wrong day Escaped or refused genetic counseling

26 Challenges Expired Infants with a Mutation Detected Family is sent a letter developed by nurse and genetic counselor A physician is notified Neonatologist Delivering Physician Family Physician Offer free genetic counseling

27 Statistics Babies Identified at risk for CF 188 one mutation 19 two mutations 28 zero mutations (no cases) 97% (227) received confirmatory sweat test 8 infants with zero mutations had in-range repeat filter papers 97% (220) received genetic counseling 94% (220) of total received face to face genetic counseling 85% received initial sweat test by 30 days of age (work group goal)

28 Expansion of GC Services Genetic Counseling is now offered for all genetic disorders including Hemoglobin Trait. Trait Counseling $ per session GC letter is not required. Pamphlet was developed (OSDH nurse and OSDH genetic counselor)

29 Acknowledgements University of Oklahoma Health Sciences Center Susan Hassed, CGC John Mulvihill, MD Oklahoma State Department of Health Edd Rhoades, MD, MPH Pam King, MPA, RN Paula Vann, BSN, RN Terry Geisler, LPN Mary Beth Wilhelm, AA

30

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background 39 th National Conference on Pediatric Health Care March 19-22, 2018 CHICAGO Disclosures The Vision and the Journey of Cystic Fibrosis: Newborn Screening to Breakthrough Therapy March 20, 2018 Cynthia

More information

Learning Objectives. Genomic Medicine and Primary Care. Clinical Applications of Genome-Level DNA Sequencing. Molecular Medicine.

Learning Objectives. Genomic Medicine and Primary Care. Clinical Applications of Genome-Level DNA Sequencing. Molecular Medicine. Presenter Disclosure Information 9:45 10:25am Genomic Medicine and Primary Care SPEAKER Wayne W. Grody, MD, PhD, FACMG, FCAP The following relationships exist related to this presentation: Wayne W. Grody,

More information

Improving Communication of Negative Newborn Screening Results. Whitney Thompson MPhil Amy Gaviglio MS, CGC Susan Berry MD

Improving Communication of Negative Newborn Screening Results. Whitney Thompson MPhil Amy Gaviglio MS, CGC Susan Berry MD Improving Communication of Negative Newborn Screening Results Whitney Thompson MPhil Amy Gaviglio MS, CGC Susan Berry MD Positive newborn blood spot results in MN Presumptive positive and borderline results

More information

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other

More information

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the. I507del. Mutation CFTR SCIENCE A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum

More information

Appendix C NEWBORN HEARING SCREENING PROJECT

Appendix C NEWBORN HEARING SCREENING PROJECT Appendix C NEWBORN HEARING SCREENING PROJECT I. WEST VIRGINIA STATE LAW All newborns born in the State of West Virginia must be screened for hearing impairment as required in WV Code 16-22A and 16-1-7,

More information

Newborn Screening: Train the Trainer PPT Questions

Newborn Screening: Train the Trainer PPT Questions Newborn Screening: Train the Trainer PPT Questions Bloodspot Screening Purpose 1. How many possible hidden disorders does the Oklahoma Newborn Screening Program screen for? A. >10 B. >20 C. >30 D. >40

More information

Newborn Screening for Cystic Fibrosis in Switzerland - Evaluation after two years

Newborn Screening for Cystic Fibrosis in Switzerland - Evaluation after two years Newborn Screening for Cystic Fibrosis in Switzerland - Evaluation after two years R. Fingerhut, T. Torresani, S. Gallati, M.H. Schoeni, C. Kuehni, C. Rueeg, M. Baumgartner, J. Barben and the Swiss CF Screening

More information

CYSTIC FIBROSIS. The condition:

CYSTIC FIBROSIS. The condition: CYSTIC FIBROSIS Both antenatal and neonatal screening for CF have been considered. Antenatal screening aims to identify fetuses affected by CF so that parents can be offered an informed choice as to whether

More information

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Lab Activity Report: Mendelian Genetics - Genetic Disorders Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population

More information

HIV Screening & Consent for Testing

HIV Screening & Consent for Testing 1. Algorithm for HIV Screening 2. Screening & Consent for HIV Testing a. Offering testing b. Counseling on HIV Risk Factors c. Pre-test Counseling d. Post-test Counseling 1. Positive Result 2. Preliminary

More information

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Disease: Gene: Cystic Fibrosis (CF) (carrier testing in reproductive

More information

Testing for Genetic Disorders that Cause Brain Damage

Testing for Genetic Disorders that Cause Brain Damage STO-132 Testing for Genetic Disorders that Cause Brain Damage Part 1: Newborn Screening Tests Matt is watching his twins, Anna and Cody, in the newborn nursery. The nurse pokes the babies heels, collects

More information

Gene Sequencing in Newborn Screening: Covering the Bases of Education and Follow-Up. Amy Gaviglio, MS, CGC February 17, 2017

Gene Sequencing in Newborn Screening: Covering the Bases of Education and Follow-Up. Amy Gaviglio, MS, CGC February 17, 2017 Gene Sequencing in Newborn Screening: Covering the Bases of Education and Follow-Up Amy Gaviglio, MS, CGC February 17, 2017 Outline Education Personnel Case Examples Considerations EDUCATION: OUR BASELINE

More information

SUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure

SUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure SUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure Subject: NEWBORN SCREENING FOR METABOLIC DEFICIENCIES Prepared By: Yolaine Henry Edit

More information

Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011

Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011 J Inherit Metab Dis (2012) 35:635 640 DOI 10.1007/s10545-012-9452-7 SSIEM SYMPOSIUM 2011 Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start

More information

Newborn Screening for Cystic Fibrosis

Newborn Screening for Cystic Fibrosis Newborn Screening for Cystic Fibrosis Three States Experience with IRT/IRT/DNA Marci Sontag PhD, Norm Brown, Dan Wright, Art Cowes, Rachel Lee, Susan Tanksley Colorado School of Public Health and Children

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex

More information

Talking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology

Talking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology Talking Genomes with Your Patients Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology Objectives Review the importance of physician familiarity with genomic testing

More information

Cystic fibrosis carrier screening in a North American population

Cystic fibrosis carrier screening in a North American population American College of Medical Genetics and Genomics Original Research Article Cystic fibrosis carrier screening in a North American population Val V. Zvereff, MD,PhD 1, Hawazin Faruki, DrPh 1, Marcia Edwards,

More information

Reducing Barriers to Risk Appropriate Cancer Genetics Services: Current Strategies

Reducing Barriers to Risk Appropriate Cancer Genetics Services: Current Strategies Reducing Barriers to Risk Appropriate Cancer Genetics Services: Current Strategies Kara J. Milliron, MS, CGC Mark D. Pearlman, MD Disclosure I am a contract genetic counselor with Informed DNA, Inc. The

More information

SARASOTA MEMORIAL HOSPITAL POLICY

SARASOTA MEMORIAL HOSPITAL POLICY PS1070 SARASOTA MEMORIAL HOSPITAL POLICY TITLE: BREAST MILK EXPOSURE POLICY #: EFFECTIVE DATE: REVIEWED/REVISED DATE: POLICY TYPE: 5/23/06 06/15/18 Clinical Non-Clinical 1 of 11 Job Title of Responsible

More information

Commonly asked questions about genetic testing for hereditary cancer

Commonly asked questions about genetic testing for hereditary cancer Commonly asked questions about genetic testing for hereditary cancer Understanding genetic testing for hereditary cancer What is hereditary cancer? In some cases, cancer is caused by genetic changes (or

More information

Survey Instrument. Appendix B

Survey Instrument. Appendix B Appendix B Survey Instrument As part of the 1992 assessment Cystic Fibrosis and DNA Tests: Implications of Carrier Screening, OTA surveyed the summer 1991 memberships of the International Society of Nurses

More information

Evening Case studies, Tuesday April 30, Vijay L. Grey McMaster University

Evening Case studies, Tuesday April 30, Vijay L. Grey McMaster University Evening Case studies, Tuesday April 30, 2013 Vijay L. Grey McMaster University Case 1 Gus Diaz was born to a 28-year-old gravida I mom who had evidence of gestational diabetes. It was managed with attention

More information

Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test

Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test February 26, 2018 John D. Thompson, PhD, MPH, MPA Director - NBS Program Washington State Public Health Laboratories What

More information

Integration Model: Services for HIV Infected Women and their Infants

Integration Model: Services for HIV Infected Women and their Infants Integration Model: Services for HIV Infected Women and their Infants Laura Armas-Kolostroubis, MD Staff Physician, Women Specialty Center Clinical Director, TX/OK AETC Parkland Health & Hospital System

More information

2017 Newborn Screening and Genetic Testing Symposium September 10, 2017

2017 Newborn Screening and Genetic Testing Symposium September 10, 2017 Removing Short-chain Acyl-CoA Dehydrogenase (SCAD) Deficiency and Isobutyryl-CoA Dehydrogenase Deficiency (IBD) from the Newborn Screening Panel: Michigan s Experience 2017 Newborn Screening and Genetic

More information

Hear better, Live fully.

Hear better, Live fully. EPIC Hearing Healthcare 3191 W. Temple Ave Suite 200 Pomona, CA 91768 Corporate Toll Free: 877.606.3742 Email: sales@epichearing.com www.epichearing.com Hear better, Live fully. ASO-2013 ASO Savings Plan

More information

Cystic fibrosis (CF) is an autosomal recessive condition

Cystic fibrosis (CF) is an autosomal recessive condition Original article Newborn screening for cystic fibrosis in Alberta: Two years of experience Margaret Lilley MSc CGC CCGC 1, Susan Christian MSc CGC 1, Stacey Hume PhD FCCMG 1, Patrick Scott PhD FCCMG FACMG

More information

For the Ongoing Management of Babies under 1 year old.

For the Ongoing Management of Babies under 1 year old. Pathway Author: Nicy Turney, Senior Nurse Professional Lead, Health Visiting 19.06.17 For the Ongoing Management of Babies under 1 year old. Check Health Records (CHR) to undertake daily checks to identify:

More information

NEONATAL SCREENING FOR CYSTIC FIBROSIS. PAST AND FUTURE. Pilot Study and RECENT INFORMATION EVA PCMA vzw Antwerp-Belgium.

NEONATAL SCREENING FOR CYSTIC FIBROSIS. PAST AND FUTURE. Pilot Study and RECENT INFORMATION EVA PCMA vzw Antwerp-Belgium. NEONATAL SCREENING FOR CYSTIC FIBROSIS. PAST AND FUTURE. Pilot Study and RECENT INFORMATION EVA PCMA vzw Antwerp-Belgium. F. Eyskens, MD, PhD 1,2 1 UZA, 2 PCMA vzw, Antwerp, Belgium Neonatal Mass Screening

More information

Routinizing HIV and HCV Testing Using an Innovative, Scalable and Sustainable Dual Testing Model

Routinizing HIV and HCV Testing Using an Innovative, Scalable and Sustainable Dual Testing Model Routinizing HIV and HCV Testing Using an Innovative, Scalable and Sustainable Dual Testing Model Catelyn Coyle MPH, MEd Public Health National Symposium June 2014 Outline Background Description of model

More information

Developed by Marion Wood and Children s Dental Needs Steering Group

Developed by Marion Wood and Children s Dental Needs Steering Group Title Document Type Issue no DNA Policy Policy Clinical Governance Support Team Use Issue date 30.05.13 Review date 30.05.15 Distribution Prepared by Dental Staff Marion Wood Developed by Marion Wood and

More information

5. Hospitals will provide the family with a copy of the Michigans Community Program: Information for Parents (MDCH /01). Copies can be ordered,

5. Hospitals will provide the family with a copy of the Michigans Community Program: Information for Parents (MDCH /01). Copies can be ordered, GUIDELINES FOR HEARING SCREENING A goal of newborn hearing screening is to ensure that all newborns receive a hearing screen before discharge from the hospital or before one month of age. All hospitals

More information

Lessons Learned Through a Recent Connecticut EHDI Program - Diagnostic Audiology Center Collaboration: One Small Change at a Time

Lessons Learned Through a Recent Connecticut EHDI Program - Diagnostic Audiology Center Collaboration: One Small Change at a Time Lessons Learned Through a Recent Connecticut EHDI Program - Diagnostic Audiology Center Collaboration: One Small Change at a Time Amy Mirizzi, MPH, CPH Early Hearing Detection & Intervention (EHDI) Program

More information

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation Chris Miller, MS, LCGC ARUP Laboratories Learning Objectives Understand the relevance of clinical information for

More information

RAH s Regional Fertility & Women s Endocrine Clinic FAQs

RAH s Regional Fertility & Women s Endocrine Clinic FAQs RAH s Regional Fertility & Women s Endocrine Clinic FAQs What changes are being made to the Regional Fertility & Women s Endocrine Clinic at the Lois Hole Hospital for Women in the Royal Alexandra Hospital

More information

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information GeneticsNow TM A Guide to Testing Hereditary Conditions in Women & Men Patient & Physician Information How can BRCA status affect your health? Everyone has BRCA1 and BRCA2 genes. However, sometimes the

More information

Optional Reporting of Sickle Cell Disease Carrier Results from Newborn Screening the Ontario model

Optional Reporting of Sickle Cell Disease Carrier Results from Newborn Screening the Ontario model Optional Reporting of Sickle Cell Disease Carrier Results from Newborn Screening the Ontario model Christine Davies, MSc, CGC Certified Genetic Counsellor Newborn Screening Ontario Overview Background

More information

Improving Communication between Doctors and Parents after Newborn Screening

Improving Communication between Doctors and Parents after Newborn Screening ORIGINAL RESEARCH Improving Communication between Doctors and Parents after Newborn Screening Michael H. Farrell, MD; Stephanie A. Christopher, MA; Audrey Tluczek, PhD, RN; Karen Kennedy-Parker, MT(ASCP);

More information

A Stepwise Approach to Embryo Selection and Implantation Success

A Stepwise Approach to Embryo Selection and Implantation Success Precise Genetic Carrier Screening An Overview A Stepwise Approach to Embryo Selection and Implantation Success Put today s most advanced genetic screening technology to work for you and your family s future.

More information

Genetic Conditions and Services: An Introduction

Genetic Conditions and Services: An Introduction Genetic Conditions and Services: An Introduction Jennifer Roberts, MC, MS, CGC Laboratory Genetics Counselor The Children s Mercy Hospital, 2017 Goals Determine which children/families may benefit from

More information

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. 1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age

More information

ICARE Initiative. Cristi Radford, MS, CGC ICARE Outreach Coordinator

ICARE Initiative. Cristi Radford, MS, CGC ICARE Outreach Coordinator ICARE Initiative Cristi Radford, MS, CGC ICARE Outreach Coordinator Agenda Overview of ICARE History Mission Benefits Patient enrollment Website contents Questions What is ICARE? Research initiative representing

More information

Green Amber Red Assurance Level

Green Amber Red Assurance Level A re-audit of the turnaround time of samples for the Sickle Cell and Thalassaemia Newborn Screening Programme, in the Manchester Newborn Screening Laboratory Clinical Audit Report May 2014 Clinical Audit

More information

Attachment 1. Newborn Screening Program Description

Attachment 1. Newborn Screening Program Description Attachment 1 Newborn Screening Program Description The core mission of Texas Newborn Screening Program is to save children s lives through the early detection of life-threatening disorders. 34 Newborn

More information

Health Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE

Health Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE CHAPTER 420-10-1 CARE AND TREATMENT OF INFANTS IDENTIFIED THROUGH THE NEWBORN SCREENING

More information

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation. Chris Miller, MS, LCGC ARUP Laboratories

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation. Chris Miller, MS, LCGC ARUP Laboratories Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation Chris Miller, MS, LCGC ARUP Laboratories Learning Objectives Explain the relevance of clinical information for genetic

More information

Broward Health s Breast Cancer Navigation Program Meeting the needs of underserved patients

Broward Health s Breast Cancer Navigation Program Meeting the needs of underserved patients Broward Health s Breast Cancer Navigation Program Meeting the needs of underserved patients by Pia Delvaille, ARNP, MSN Broward Health, a nonprofit community health system, is one of the ten largest public

More information

Heard About Genetic Counseling? What Does it Mean for You, Patients, and Families?

Heard About Genetic Counseling? What Does it Mean for You, Patients, and Families? Heard About Genetic Counseling? What Does it Mean for You, Patients, and Families? Karin M. Dent, MS, LCGC Assistant Professor, Pediatrics Thursday, August 30 12:00-12:30pm Central Time Out for Genetics

More information

Genetics and Genetic Testing for Autism:

Genetics and Genetic Testing for Autism: STAR Training 2/22/2018 Genetics and Genetic Testing for Autism: Demystifying the Journey to Find a Cause Alyssa (Ah leesa) Blesson, MGC, CGC Certified Genetic Counselor Center for Autism and Related Disorders

More information

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use Effective Date: May 19, 2008 Revised Date: August 18, 2015 Approved by: Thomas M Tocher, MD, MPH, Chief Clinical Officer Policy Number: MED Policy 313 Title: Pain Management Long Term Opioid Use POLICY

More information

Support. Overview. Auditory Dys-synchrony. Auditory Brainstem Response. Potential Causes

Support. Overview. Auditory Dys-synchrony. Auditory Brainstem Response. Potential Causes Potential Role of Genetic Testing in Auditory Neuropathy/Dys-synchrony Christina Runge-Samuelson, Ph.D., CCC-A Associate Professor Co-Director, Koss Cochlear Implant Program Department of tolaryngology

More information

ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative

ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative ORIGINAL ARTICLE ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative Waleed M. Alazmi, MD, Evan L. Fogel, MD, Suzette Schmidt, RN, James L. Watkins, MD,

More information

Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH

Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH University of Pittsburgh Medical Center Disclosures Presenter has no financial interests to

More information

NEWBORN SCREENING in Massachusetts: Answers for you and your baby

NEWBORN SCREENING in Massachusetts: Answers for you and your baby NEWBORN SCREENING in Massachusetts: Answers for you and your baby The New England Newborn Screening Program University of Massachusetts Medical School 305 South St. Jamaica Plain, MA 02130 617-983-6300

More information

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Introduction to Evaluating Hereditary Risk Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Objectives Describe genetic counseling and risk assessment Understand

More information

REFERENCE LABORATORY. Regular Hours - Monday through Friday 8:00 AM to 4:00 PM. On-Call Staff - Evenings, Nights, Weekend and Holidays.

REFERENCE LABORATORY. Regular Hours - Monday through Friday 8:00 AM to 4:00 PM. On-Call Staff - Evenings, Nights, Weekend and Holidays. I. REFERENCE LABORATORY HOURS OF OPERATION: Regular Hours - Monday through Friday 8:00 AM to 4:00 PM. On-Call Staff - Evenings, Nights, Weekend and Holidays. All Reference Lab procedures are subject to

More information

Screening Newborns for Congenital Disorders

Screening Newborns for Congenital Disorders Screening Newborns for Congenital Disorders Gary L. Hoffman, BS; Ronald H. Laessig, PhD ABSTRACT The Newborn Screening Laboratory at the Wisconsin State Laboratory of Hygiene (WSLH) tests all newborn babies

More information

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London Epilepsy Genetics Team Professor Deb Pal

More information

Quick Reference Guide for Health Care Providers

Quick Reference Guide for Health Care Providers Quick Reference Guide for Health Care Providers Breast and Cervical Cancer Screening and Treatment in Kentucky Kentucky Cancer Program Kentucky Department for Public Health For more information, contact:

More information

Smoking Cessation and Pharmacy Care Record (PCR)

Smoking Cessation and Pharmacy Care Record (PCR) 1 Smoking Cessation and Pharmacy Care Record (PCR) Before starting a new assessment check the following: Does the patient consent to Follow Up? If No, do not proceed as it is no longer permitted under

More information

Friday, January 4. Bell Work:

Friday, January 4. Bell Work: Friday, January 4 Bell Work: Red green colorblindness is an X linked trait and is recessive. A male who is normal marries a woman who is a carrier, what is the phenotypic ratio of their offspring? 1 Genetic

More information

110 DISEASES 3 DISEASES GENE TIC COUNSELING CARRIERMAP Recombine. Others. 30+ minute clinical genetic counseling session.

110 DISEASES 3 DISEASES GENE TIC COUNSELING CARRIERMAP Recombine. Others. 30+ minute clinical genetic counseling session. Recombine CARRIERMAP GENE TIC COUNSELING Genetic diseases, though individually rare, are collectively common; thus, assessing carrier status is one of the most important things you can do for your patients.

More information

NEWBORN SCREENING PRENATAL CURRICULUM

NEWBORN SCREENING PRENATAL CURRICULUM NEWBORN SCREENING PRENATAL CURRICULUM GOAL 1: Explain why newborn screening is important GOAL 2: How newborn screening is performed GOAL 3: The newborn screening test results GOAL 4: Follow-up to newborn

More information

Grand Rounds 6. Lesson Summary: Student Learning Objectives: Standards: Materials:

Grand Rounds 6. Lesson Summary: Student Learning Objectives: Standards: Materials: Grand Rounds 6 Lesson Summary: Building on the previous activity, students will present a summary of their patient case along with the lab results they found in a grand rounds fashion. This activity allows

More information

LOUISIANA MEDICAID PROGRAM ISSUED: 09/28/12 REPLACED: 02/01/12 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 7

LOUISIANA MEDICAID PROGRAM ISSUED: 09/28/12 REPLACED: 02/01/12 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 7 Early and Periodic Screening, Diagnosis and Treatment (EPSDT) Medicaid recipients under 21 years of age are entitled to receive all medically necessary health care, diagnostic services, treatment and other

More information

Genetic Testing Program for Huntington s Disease

Genetic Testing Program for Huntington s Disease Genetic Testing Program for Huntington s Disease Genetic testing for the Huntington s Disease (HD) gene expansion became possible in 1993. This test can be used to confirm the diagnosis in someone who

More information

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing

More information

BRCAnowTM It s Your Decision

BRCAnowTM It s Your Decision Hereditary Breast and Ovarian Cancer BRCAnowTM It s Your Decision Patient & Physician Information What is BRCA? The breast cancer genes BRCA1 and BRCA2 are found within an individual s normal genetic makeup;

More information

*Please feel free to ask your child s doctor for help with filling out this form or contact our 22q Center Nurse at

*Please feel free to ask your child s doctor for help with filling out this form or contact our 22q Center Nurse at Child s Name Today s Date Parent(s)/Guardian(s) Child s DOB Age Address Phone Parent s email Who is completing this form (name and relation to patient) Insurance Provider Subscriber s Name Subscriber ID

More information

INPATIENT SCREENING PROTOCOL

INPATIENT SCREENING PROTOCOL INPATIENT SCREENING PROTOCOL During the maternity stay, a designated hospital staff member will: Inform parents of the hospital s universal newborn hearing screening program. Obtain informed consent for

More information

IHN-CCO DST Final Report and Evaluation

IHN-CCO DST Final Report and Evaluation IHN-CCO DST Final Report and Evaluation Breastfeeding Support Services July 2016 to September 2018 Summary: This pilot reduced the barriers new mothers have in being able to successfully breastfeed their

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Wells JM, Farris RF, Gosdin TA, et al. Pulmonary

More information

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there

More information

5.20 West Virginia BEST START Breastfeeding Program

5.20 West Virginia BEST START Breastfeeding Program POLICY: West Virginia WIC The purpose of the West Virginia BEST START Breastfeeding Program is to increase the frequency and duration of breastfeeding among women in the WIC Program per set goals cited

More information

Objectives: Substance Abuse Treatment & Engaging Families. Families First Background 7/8/2016

Objectives: Substance Abuse Treatment & Engaging Families. Families First Background 7/8/2016 Substance Abuse Treatment & Engaging Families Gloria Cruz-Bernal, MSW, MPA Maricopa County Juvenile Court Family Treatment (FTC) And Missy Longe, MC LPC LISAC Terros Families First Objectives: 1. Program

More information

Kansas Successful Strategies in Reducing Loss to Follow-Up/Loss to Documentation

Kansas Successful Strategies in Reducing Loss to Follow-Up/Loss to Documentation Kansas Successful Strategies in Reducing Loss to Follow-Up/Loss to Documentation 13th Annual EHDI Conference Jacksonville, FL Liz Abbey, M.A., Audiologist/Kansas EHDI Coordinator Kelly Barr, Kansas Data

More information

SUBCHAPTER 43H - SICKLE CELL SYNDROME: GENETIC COUNSELING: CHILDREN AND YOUTH SECTION SECTION SICKLE CELL SYNDROME PROGRAM

SUBCHAPTER 43H - SICKLE CELL SYNDROME: GENETIC COUNSELING: CHILDREN AND YOUTH SECTION SECTION SICKLE CELL SYNDROME PROGRAM SUBCHAPTER 43H - SICKLE CELL SYNDROME: GENETIC COUNSELING: CHILDREN AND YOUTH SECTION SECTION.0100 - SICKLE CELL SYNDROME PROGRAM 10A NCAC 43H.0101 10A NCAC 43H.0102 EDUCATION 10A NCAC 43H.0103 TESTING

More information

thorough physical and laboratory investigations fail to define the etiology of hearing loss. (2000, p. 16). In a report produced for the Maternal and

thorough physical and laboratory investigations fail to define the etiology of hearing loss. (2000, p. 16). In a report produced for the Maternal and GUIDELINES FOR GENETIC EVALUATON REFERRAL The prevalence of permanent hearing loss in infants is estimated to be 2-3/1000 in the United States (Finitzo et al., 1998; Prieve et al., 2000). One or both ears

More information

Hypertrophy of liver Neonatal hypoglycemia Omphalocele Large for gestational age Other:

Hypertrophy of liver Neonatal hypoglycemia Omphalocele Large for gestational age Other: REQUEST FOR BECKWITH-WIEDEMANN SYNDROME (BWS) TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION

More information

History of Screening for CF and CH in New Zealand. Dianne Webster Diane Casey Kathy Bendikson Richard MacKay Paul Hofman

History of Screening for CF and CH in New Zealand. Dianne Webster Diane Casey Kathy Bendikson Richard MacKay Paul Hofman History of Screening for CF and CH in New Zealand Dianne Webster Diane Casey Kathy Bendikson Richard MacKay Paul Hofman New Zealand Country is small 268680 km 2 Population 4.4M Maori 15% Pacific 7% Asian

More information

Long-term Follow-up for Cystic Fibrosis: A Collaboration with the Cystic Fibrosis Foundation

Long-term Follow-up for Cystic Fibrosis: A Collaboration with the Cystic Fibrosis Foundation Long-term Follow-up for Cystic Fibrosis: A Collaboration with the Cystic Fibrosis Foundation Beth Vogel, MS, CGC NYS Newborn Screening Program Wadsworth Center Outline Introduction Matching Long-term follow-up

More information

The Future of CF Therapy

The Future of CF Therapy The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy

More information

New Haven/Fairfield Counties Ryan White Part A Program Oral Health Standard of Care

New Haven/Fairfield Counties Ryan White Part A Program Oral Health Standard of Care DENTAL/ORAL HEALTH I. DEFINITION OF SERVICE Support for Oral Health Services including diagnostic, preventive, and therapeutic dental care that is in compliance with state dental practice laws, includes

More information

WELCOME TO SOUTHWEST CHILDREN S CENTER, P.A.

WELCOME TO SOUTHWEST CHILDREN S CENTER, P.A. WELCOME TO SOUTHWEST CHILDREN S CENTER, P.A. Marshall J. Benbow, M.D., FAAP Tina H. Boylston, M.D., FAAP Shelly M. McNair, M.D., FAAP Rose C. Cofer, M.D., FAAP Shannon M. Austin, M.D., FAAP L. Patrick

More information

Chapter 5 Nutrition Education. Table of Contents

Chapter 5 Nutrition Education. Table of Contents Chapter 5 Nutrition Education Table of Contents This chapter describes WIC's nutrition education component, including required nutrition education topics, frequency of nutrition education contacts, providing

More information

Counsyl Foresight Carrier Screen. Utmost confidence in every result

Counsyl Foresight Carrier Screen. Utmost confidence in every result Counsyl Foresight Carrier Screen Utmost confidence in every result EXTENDING THE BENEFITS OF CARRIER SCREENING Elevate quality of care with expanded carrier screening (ECS) Carrier screening is used to

More information

HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS

HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS INFORMATION SHEET HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS Health assessments of New Zealand visa applicants are conducted by the International Organization for Migration (IOM) on behalf of Immigration

More information

4th International Summer School on Rare Disease and Orphan Drug Registries

4th International Summer School on Rare Disease and Orphan Drug Registries 4th International Summer School on Rare Disease and Orphan Drug Registries Experiences with building and managing a registry: The Italian Cystic Fibrosis Patients Registry Marco Salvatore, National Center

More information

Cystic Fibrosis. Information for Caregivers

Cystic Fibrosis. Information for Caregivers Cystic Fibrosis Information for Caregivers Arkansas Children s Hospital is an accredited Cystic Fibrosis Care Center by the National Cystic Fibrosis Foundation Cystic Fibrosis: Information for Caregivers

More information

[APPLICANT, PLEASE LEAVE THIS AREA

[APPLICANT, PLEASE LEAVE THIS AREA ATTUD TREATMENT PROGRAM WEBSITE LISTING: APPLICATION FORM This form is intended to provide a mechanism by which treatment providers and programs can apply to list their services on the ATTUD web site (www.attud.org).

More information

Completed applications can be submitted either by mail or to:

Completed applications can be submitted either by mail or  to: Dear Sir or Madam: Thank you for your interest in the Feldenkrais Foundation s Low Fee Clinic. This popular clinic provides individual Feldenkrais Functional Integration sessions at a reduced rate for

More information

Because Knowledge is a Powerful Tool. Focused on Patients

Because Knowledge is a Powerful Tool. Focused on Patients Because Knowledge is a Powerful Tool. Focused on Patients As the availability of genetic testing increases, a person may face many questions and choices. A Genetic Counselor provides assistance in understanding

More information

-VFC Providers Influenza Vaccine and Preparedness Survey: Oregon-

-VFC Providers Influenza Vaccine and Preparedness Survey: Oregon- -VFC Providers Influenza Vaccine and Preparedness Survey: Oregon- Directions: Please fill out the below survey. Once completed please fax your responses back to 404-712-8345, Attn. Allison Chamberlain.

More information

4. A homozygous tall plant and a heterozygous tall plant are crossed. What is the percent probability of short offspring?

4. A homozygous tall plant and a heterozygous tall plant are crossed. What is the percent probability of short offspring? LEVEL ZERO VOICE POP QUIZ (4 minutes, individual work): 1. Define gene: 2. Define phenotype: 3. A heterozygous white rabbit is crossed with a homozygous black rabbit. If they have 160 offspring, how many

More information

HAART to HEART: A multidisicplinary adherence support and evaluation program in Ryan-White funded community health centers

HAART to HEART: A multidisicplinary adherence support and evaluation program in Ryan-White funded community health centers HAART to HEART: A multidisicplinary adherence support and evaluation program in Ryan-White funded community health centers Lisa R Hirschhorn, Susan Goldin, Theresa Meehan, Israel Flores, William Woods,

More information

Multi-Center Feasibility Study of a Neonatal IRT-PAP Screening Concept for Cystic Fibrosis

Multi-Center Feasibility Study of a Neonatal IRT-PAP Screening Concept for Cystic Fibrosis Multi-Center Feasibility Study of a Neonatal IRT-PAP Screening Concept for Cystic Fibrosis Participating Sites: Wisconsin State Laboratory of Hygiene, USA Gary Hoffman New England Newborn Screening Program

More information